NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in innovative mental health care, will announce its financial results for Q3 2022 on July 14, 2022, after market close. A conference call and webcast will follow at 5:30 p.m. ET to discuss performance and initiatives. Interested participants can register for the live session and access the archived version later. Numinus aims to transform mental health treatment through psychedelic-assisted therapies, focusing on healing rather than merely managing symptoms.

Numinus Wellness Inc. (NUMIF) announced a major rebranding initiative to unify its presence across North America, set to be completed by the end of 2022. The new visual identity aims to enhance brand awareness and market presence as Numinus continues its growth in providing psychedelic-assisted therapies for mental health. The rebranding will be executed in phases, starting with current assets and later including subsidiaries. This strategic move reflects Numinus' commitment to innovative mental health care and aims to strengthen connections with its audiences.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced its subsidiary, Numinus Bioscience Inc., has filed a patent application with the World Intellectual Property Organization (WIPO) for a rapid psilocybin production process. This enhances its initial USPTO filing from June 2021 and aims to secure international patent protection across member states. The process is designed to improve production efficiency while lowering commercialization costs, expanding potential therapeutic applications to various fungi. The company emphasizes its commitment to advancing mental health treatments through innovative research and development.

Numinus Wellness has completed its acquisition of Novamind, following necessary shareholder and court approvals. Numinus shareholders received 0.84 shares of Numinus for each Novamind share. The transaction enhances Numinus' operations, expanding its clinics and research facilities, and is projected to increase annual revenues to C$11.9 million. Key executive appointments include Reid Robison as Chief Clinical Officer and Paul Thielking as Chief Science Officer. The integration will allow for a broader range of mental health services and continued growth opportunities.

Novamind Inc. has successfully completed its acquisition by Numinus Wellness Inc., following the Supreme Court of British Columbia's final order. As part of this plan of arrangement, holders of Novamind shares will receive 0.84 of a Numinus share for each Novamind share they own. Consequently, Novamind shares will be delisted from the Canadian Securities Exchange, and the company plans to cease its public reporting obligations. This acquisition is anticipated to enhance Numinus's portfolio in the psychedelic medicine sector, positioning the combined entity for future growth.

Numinus Wellness Inc. (NUMIF) announced that its shareholders and Novamind shareholders have approved the acquisition of Novamind Inc. The transaction is set to be completed on or about June 10, 2022. Numinus aims to establish itself as a leader in mental wellness in North America, offering innovative therapies including Ketamine and psychedelic-assisted treatments. Over 98% of Numinus shareholders voted in favor of issuing up to 63,010,034 common shares to Novamind securityholders. The completion is pending approval from the British Columbia Supreme Court and standard closing conditions.

Numinus Wellness (TSX: NUMI) has received a positive recommendation from Institutional Shareholder Services (ISS) regarding its proposed acquisition of Novamind. ISS advises shareholders to vote "FOR" the share issuance related to this acquisition, emphasizing expected cost-saving synergies and strategic alignment in the same sector. The Numinus Special Shareholder Meeting is set for June 8, 2022, where shareholders will vote on the Share Issuance Resolution to authorize the issuance of up to 63,010,034 common shares in connection with the acquisition.

Numinus Wellness Inc. has received Health Canada approval to provide psilocybin-assisted therapy for treatment-resistant depression, marking a significant milestone as the first such treatment outside clinical trials. This therapy will be conducted at their Montreal clinic, using synthetic psilocybin sourced from Psygen Labs. The approval allows for innovative mental health treatment under Health Canada's Special Access Program (SAP), which facilitates access to psychedelic compounds for patients who have failed conventional treatments. Numinus aims to expand its offerings in Canada, enhancing access to evidence-based psychedelic therapies.

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:30 p.m. ET. Founder and CEO Payton Nyquvest will discuss Numinus’ innovative mental health treatments, including psychedelic-assisted therapies. Attendees can register for the event here. The chat will also be available via live webcast and archived on Numinus’ investor relations website.